IDEMIA
9.10.2018 14:55:11 CEST | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, today announces its partnership with JCB, the only international payment brand based in Japan, to launch Google Pay in Japan.
Users will be able to make contactless mobile payments in store using their JCB branded credit, debit, and prepaid cards enrolled in their Google Pay, at places such as convenience stores, supermarkets, drug stores and other shops where QUICPay is accepted.
To enable Google Pay for JCB cardholders, JCB leverages an agnostic and scalable payment card tokenization and digitization infrastructure, the JCB Tokenization Platform (JTP). It relies on IDEMIA’s field-proven digital payment solution. It allows not only JCB, but also its issuing and processing partners to integrate with Google Pay and offer real-time enrolment, provisioning and tokenization capabilities. Users in Japan can, therefore, add their JCB cards in the Google Pay app on their Osaifu Keitai-compatible phones equipped with Android 5.0 or higher version.
We are delighted to be able to provide our customers with the ability to use Google Pay by leveraging QUICPay’s wide acceptance network in Japan.” said Masaki Yokawa, Executive Vice-President for Brand Business at JCB. “We believe the service will enhance the convenience and experience for JCB card members with the simple and intuitive user interface. JTP plays an integral part for making this happen, and we are proud to have worked with IDEMIA, who has a proven track record in this area, in order to add the Google Pay capability to the platform.”
Nobuyoshi NEZU, Representative director at IDEMIA Japan declared: "We are proud to have worked together with JCB in the deployment of Google Pay in Japan. This represents another milestone in our long-term partnership. IDEMIA is the mobile payment enablement partner of choice for JCB, by offering IDEMIA’s field-proven Digital Enablement Platform. IDEMIA’s technology and services are deployed at scale with tens of millions of cards digitized so far across the world.”
For more information about Google Pay, visit https://pay.google.com/about/ or get the Google Pay app
- Google Pay and Google are trademarks of Google LLC.
- QUICPay is the contactless payment product developed by JCB for the Japanese market. QUICPay is a registered trademark of JCB for its contactless payment solution.
- Osaifu-Keitai is the Standard mobile payment system, only available to subscribers in Japan. Osaifu Keitai is a trademark of NTT DOCOMO, INC.
About JCB
JCB is a major global payment brand and a leading
payment card issuer and acquirer in Japan. JCB launched its card
business in Japan in 1961 and began expanding worldwide in 1981. As part
of its international growth strategy, JCB has formed alliances with
hundreds of leading banks and financial institutions globally to
increase merchant coverage and card member base. As a comprehensive
payment solution provider, JCB commits to provide responsive and
high-quality service and products to all customers worldwide. For more
information, please visit: www.global.jcb/en/
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in
Augmented Identity for an increasingly digital world, with the ambition
to empower citizens and consumers alike to interact, pay, connect,
travel and vote in ways that are now possible in a connected environment.
Securing
our identity has become mission critical in the world we live in today.
By standing for Augmented Identity, we reinvent the way we think,
produce, use and protect this asset, whether for individuals or for
objects. We ensure privacy and trust as well as guarantee secure,
authenticated and verifiable transactions for international clients from
Financial, Telecom, Identity, Public Security and IoT sectors.
OT
(Oberthur Technologies) and Safran Identity & Security (Morpho) have
joined forces to form IDEMIA. With close to $3 billion in revenues and
14,000 employees around the world, IDEMIA serves clients in 180
countries.
For more information, visit www.idemia.com
/ Follow @IdemiaGroup
on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20181009005684/en/
Contact:
Press Havas Paris Hanna SEBBAH idemia@havas.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom